Testing
GMMA-based vaccine
OMV
adjuvant
immune response
unadsorbed GMMA
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
21
02
2024
revised:
29
03
2024
accepted:
02
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Shigellosis is one of the leading causes of diarrheal disease in low- and middle-income countries, particularly in young children, and is more often associated with antimicrobial resistance. Therefore, a preventive vaccine against shigellosis is an urgent medical need. We have proposed Generalised Modules for Membrane Antigens (GMMA) as an innovative delivery system for
Identifiants
pubmed: 38675229
pii: pharmaceutics16040568
doi: 10.3390/pharmaceutics16040568
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : GlaxoSmithKline (Italy)
ID : This work was undertaken at the request of , sponsored and funded by GlaxoSmithKline Biolog-icals SA. GSK Vaccines Institute of Global Health is an affiliate of GlaxoSmithKline Biologicals SA.